Yongxia Shi

机构：Guangzhou Regenerative Medicine and Health Guangdong Laboratory

发表论文 10 篇 · 总被引 74 次 · h-index 3

代表论文

• The adenosine analog prodrug ATV006 is orally bioavailable and has preclinical efficacy against parental SARS-CoV-2 and variants (2022 · Science Translational Medicine · 被引 44)
• SARS‐CoV‐2 infection activates CREB/CBP in cellular cyclic AMP‐dependent pathways (2022 · Journal of Medical Virology · 被引 18)
• Isolation and genomic characterization of Chikungunya virus during the 2025 outbreak in Foshan, China (2025 · Emerging Microbes & Infections · 被引 9)
• Integrated multiplex PCR and metatranscriptomics reveal upper-lower airway microbial landscapes in pediatric respiratory infections (2026 · Virologica Sinica · 被引 1)
• Targeting the host factor HGS–viral membrane protein interaction in coronavirus infection (2025 · Journal of Clinical Investigation · 被引 1)
• Targeting the host factor HGS-viral membrane protein interaction in coronavirus infection (2025 · bioRxiv (Cold Spring Harbor Laboratory) · 被引 1)